Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for IDYA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -111.66M
March 31, 2026 -85.93M
December 31, 2025 -71.10M
September 30, 2025 -102.26M
June 30, 2025 -293.70M
March 31, 2025 -264.11M
December 31, 2024 -247.58M
September 30, 2024 -149.68M
June 30, 2024 -130.62M
March 31, 2024 -131.20M
December 31, 2023 -115.22M
September 30, 2023 -114.85M
June 30, 2023 -108.84M
March 31, 2023 -95.37M
December 31, 2022 -87.18M
September 30, 2022 -80.46M
Date Value
June 30, 2022 -68.76M
March 31, 2022 -61.70M
December 31, 2021 -55.78M
September 30, 2021 -50.72M
June 30, 2021 51.96M
March 31, 2021 51.28M
December 31, 2020 55.46M
September 30, 2020 58.35M
June 30, 2020 -42.41M
March 31, 2020 -39.07M
December 31, 2019 -39.31M
September 30, 2019 -38.08M
June 30, 2019 -36.22M
March 31, 2019 -31.88M
December 31, 2018 -27.62M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Xencor, Inc. -205.81M
UroGen Pharma Ltd. -170.43M
MeiraGTx Holdings Plc 13.69M
ACADIA Pharmaceuticals, Inc. 160.32M
Alnylam Pharmaceuticals, Inc. 885.89M